Literature DB >> 19821881

Canine platelet transfusions.

Mary Beth Callan1, Elizabeth H Appleman, Bruce S Sachais.   

Abstract

OBJECTIVE: To review potential platelet storage options, guidelines for administration of platelets, and adverse events associated with platelet transfusions. DATA SOURCES: Data sources included original research publications and scientific reviews. HUMAN DATA SYNTHESIS: Transfusion of platelet concentrates (PCs) plays a key role in the management of patients with severe thrombocytopenia. Currently PCs are stored at 22 degrees C under continuous gentle agitation for up to 5 days. Chilling of platelets is associated with rapid clearance of transfused platelets, and galactosylation of platelets has proven unsuccessful in prolonging platelet survival. Although approved by the American Association of Blood Banks, cryopreservation of human platelets in 6% DMSO largely remains a research technique. Pre-storage leukoreduction of PCs has reduced but not eliminated acute inflammatory transfusion reactions, with platelet inflammatory mediators contributing to such reactions. VETERINARY DATA SYNTHESIS: Canine plateletpheresis allows collection of a concentrate with a high platelet yield, typically 3-4.5 x 10(11) versus <1 x 10(11) for whole blood-derived platelets, improving the ability to provide sufficient platelets to meet the recipient's transfusion needs. Cryopreservation of canine platelets in 6% DMSO offers immediate availability of platelets, with an acceptable posttransfusion in vivo platelet recovery and half-life of 50% and 2 days, respectively. While data on administration of rehydrated lyophilized platelets in bleeding animal models are encouraging, due to a short lifespan (min) posttransfusion, their use will be limited to control of active bleeding, without a sustained increase in platelet count.
CONCLUSIONS: Fresh PC remains the product of choice for control of bleeding due to severe thrombocytopenia or thrombopathia. While cryopreservation and lyophilization of canine platelets offer the benefits of immediate availability and long-term storage, the compromise is decreased in vivo recovery and survival of platelets and some degree of impaired function, though such products could still be life saving.

Entities:  

Mesh:

Year:  2009        PMID: 19821881     DOI: 10.1111/j.1476-4431.2009.00454.x

Source DB:  PubMed          Journal:  J Vet Emerg Crit Care (San Antonio)        ISSN: 1476-4431


  5 in total

1.  Equine platelet concentrate preparation and validation.

Authors:  Rana Bozorgmanesh; K Gary Magdesian; Julie W Sutton-Burges; Sean D Owens; Fern Tablin
Journal:  J Vet Intern Med       Date:  2019-03-13       Impact factor: 3.333

Review 2.  Fluids of the Future.

Authors:  Thomas H Edwards; Guillaume L Hoareau
Journal:  Front Vet Sci       Date:  2021-01-21

Review 3.  Hemostatic Dysfunction in Dogs Naturally Infected with Angiostrongylus vasorum-A Narrative Review.

Authors:  Jakob L Willesen; Rebecca Langhorn; Lise N Nielsen
Journal:  Pathogens       Date:  2022-02-14

4.  Splenectomy in the management of primary immune-mediated hemolytic anemia and primary immune-mediated thrombocytopenia in dogs.

Authors:  Jason P Bestwick; James Warland; Barbara J Skelly; James W Swann; Barbara Glanemann; Nick Bexfield; Zeta Gkoka; David J Walker; Paolo Silvestrini; Sophie Adamantos; Mayank Seth
Journal:  J Vet Intern Med       Date:  2022-07-07       Impact factor: 3.175

5.  Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: A multicenter randomized clinical trial.

Authors:  Robert Goggs; Benjamin M Brainard; Dana N LeVine; Janine Calabro; Karyn Harrell; Tracy Mills; Richard Stone; Benjamin Davidson; Christine Iacovetta; Lauren Harris; John Gicking; Mary Aslanian; Ashley Ziegler; Brenda Fulcher; Teresa Lightfoot; Meredith Miller; John Loftus; Rebecca Walton; April Blong; Jennifer Kishbaugh; Anne S Hale
Journal:  J Vet Intern Med       Date:  2020-10-05       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.